September 2015 Issue of The Medicine Maker

Drug makers and regulators are taking steps towards transparency, but is it enough?

Do Brazilian wasps hold the promise of a new anticancer therapy? The answer is in the sting

Continuous monitoring of pharma products with an innovative matchbox-sized laser

Drug companies claim that off-label drug promotion is protected by freedom of speech.

DNA vaccine helps turn patients’ own cells into antibody-producing factories.

CPhI Worldwide 2015 in Madrid is just around the corner. Are you ready for showtime?

More quality control testing is needed to ensure that antibiotics don't become targets for fraudsters.

Redeploying or selling equipment without sufficient expertise can lead to liability risks.

Knowledge managementof QbD can help bring benefits in medicine manufacture.

The FDA approved the first 3D-printed drug in August; what other hot research projects are set to shape pharma’s 3D future?

Clive Roberts from the UK's University of Nottingham describes his team's work with big pharma on printing medicines.

Our research team has been investigating innovative manufacturing technologies to develop custom drug delivery systems, and one area of interest for us is 3D printing.

Aprecia Pharmaceuticals has recently received the first FDA approval for a drug made with 3D printing technology.

Lee Cronin is using 3D printing systems to perform some very clever and unique chemistry.

Parallel to the development of 3D printing, techniques have also been developed that can print living cells.

Earlier this year, a research group used 3D printing to give tablets a geometric makeover.

What is 3D printing? Our 101 class will get yopu up to speed with the basics and history of the technique.

Although our September cover feature focused on 3D printing, it is not the only printing technique that is being investigated in pharma applications.

Often touted as ‘magic bullets’ against cancer, antibody-drug conjugates (ADCs) aim to combine the effectiveness of chemotherapy...

Learning when to abandon an R&D project can open the door to potential future gains.

Despite clinical failures in the 1990s, pharma is (cautiously) ready to try again with oral peptide formulations.

Is it time to update your resume and fine-tune your interview skills?

Sitting Down With... David Baltimore, Nobel Laureate, President Emeritus and Robert Andrews Millikan Professor of Biology, California Institute of Technology, USA.

There are key benefits to having an industry standard for E&L studies – but a standard is only the beginning.